What controversy? Eli Lilly plots Alzheimer's BLA filing later this year as FDA taps more anti-amyloid drugs as breakthroughs
The FDA is keeping the good news coming for Alzheimer’s drug developers. And Eli Lilly is taking them up on it.
Amid continued controversy around …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
